Profiling serum biomarkers in patients with COPD: associations with clinical parameters
Profiling serum biomarkers in patients with COPD: associations with clinical parameters
复制标题
DOI：
10.1136/thx.2006.064428
复制
发表时间：
2007-07-01
期刊：
影响因子：
10
通讯作者：
Celli, Bartolome
中科院分区：
文献类型：
--
作者：
Pinto-Plata, Victor;Toso, John;Celli, Bartolome
背景：慢性阻塞性肺疾病(COPD)是一种与严重的全身性后果相关的炎症性肺部疾病。对系统性表现的认识激发了对这些患者循环生物标记物的识别兴趣。方法：采用新型蛋白质芯片技术对48例慢性阻塞性肺疾病患者(男65%，S 1例，55%)和48例正常对照血清中多种蛋白质组分进行了系统分析。测量人体测量学参数、肺功能试验、6分钟步行距离、BODE指数和恶化次数，并将这些结果与PMP测量的143项血清标志物的基线水平进行相关性分析。结果：通过计算每一类对COPD的预测值(偏最小二乘判别分析)，识别并排序了30个生物标志物类。从19个预测最好的类群中，根据它们的病理生理学特征(化学物质、炎症、组织破坏和修复)选择2-3个生物标记物，并检验它们与临床重要终点的关系的统计学意义。筛选出的24项标志物与S用力呼气量、一氧化碳转移因子、6分钟步行距离、BODE指数和病情加重次数相关(P<；0.01)。结论：PMP技术可用于慢性阻塞性肺疾病患者潜在标志物的识别。选定的血清标记物组合与这些患者预后的重要临床预测指标有关。
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease associated with significant systemic consequences. Recognition of the systemic manifestations has stimulated interest in identifying circulating biomarkers in these patients. A systematic analysis was undertaken of multiple protein analytes in the serum of well characterised patients with COPD and matched controls using novel protein microarray platform (PMP) technology.Methods: Forty-eight patients (65% men) with COPD (forced expiratory volume in 1 s < 55%) and 48 matched controls were studied. Anthropometric parameters, pulmonary function tests, 6-minute walk distance, the BODE index and the number of exacerbations were measured and the association of these outcomes with the baseline levels of 143 serum biomarkers measured by PMP was explored.Results: Thirty biomarker clusters were identified and ranked by computing the predictive value of each cluster for COPD (partial least squares discriminant analysis). From the 19 best predictive clusters, 2-3 biomarkers were selected based on their pathophysiological profile (chemoattractants, inflammation, tissue destruction and repair) and the statistical significance of their relationship with clinically important end points was tested. The selected panel of 24 biomarkers correlated (p < 0.01) with forced expiratory volume in 1 s, carbon monoxide transfer factor, 6-minute walk distance, BODE index and exacerbation frequency.Conclusion: PMP technology can be useful in identifying potential biomarkers in patients with COPD. Panels of selected serum markers are associated with important clinical predictors of outcome in these patients.